Andrew A. Lane, MD, PhD
Harvard University
H-index: 36
North America-United States
Top articles of Andrew A. Lane, MD, PhD
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia | Blood Advances | Andrew A Lane Jacqueline S Garcia Evangeline G Raulston Jada L Garzon Ilene Galinsky | 2024/2/13 |
Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow | Modern Pathology | Sam Sadigh Daniel J DeAngelo Jacqueline S Garcia Robert P Hasserjian Christopher B Hergott | 2024/1/1 |
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm | Blood Advances | Caterina Giovanna Valentini Livio Pagano | 2023/11/28 |
Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival | Blood Advances | Shai Shimony Julia Keating Christopher J Fay Marlise R Luskin Donna S Neuberg | 2024/4/16 |
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study | The Lancet Oncology | Naval G Daver Pau Montesinos Daniel J DeAngelo Eunice S Wang Nikolaos Papadantonakis | 2024/3/1 |
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations | Naveen Pemmaraju Yazan F Madanat David Rizzieri Salman Fazal Raajit Rampal | 2024/2/23 | |
S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID … | HemaSphere | Naveen Pemmaraju Giovanni Martinelli Pau Montesinos Luca Mazzarella Daniel J Deangelo | 2023/8/1 |
Down syndrome and leukemia: from basic mechanisms to clinical advances | André Baruchel Jean-Pierre Bourquin John Crispino Sergi Cuartero Henrik Hasle | 2023/10/10 | |
Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International … | Blood | Stacey M Frumm Haesook T Kim Amar H Kelkar Vincent T Ho Mahasweta Gooptu | 2023/11/28 |
Loss of the Y chromosome as a candidate driver in solid tumors | Cancer Research | Meifang Qi Esther Rheinbay Andrew A Lane Jiali Pang Irene Mitsiades | 2023/4/4 |
Loss of chromosome Y in primary tumors | Cell | Meifang Qi Jiali Pang Irene Mitsiades Andrew A Lane Esther Rheinbay | 2023/7/6 |
DDX41: here, there…and everywhere | Blood | Christopher R Reilly Andrew A Lane | 2023/10/5 |
A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and … | Blood | Stacey M Frumm Haesook T Kim Amar H Kelkar Vincent T Ho Mahasweta Gooptu | 2023/11/28 |
Novel use of acitretin for posttransplant Grover’s disease and cutaneous graft versus host disease | JAAD Case Reports | Neha Gupta Cesar A Virgen Amrita Goyal Andrew A Lane Joseph H Antin | 2023/3/1 |
Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin | Nature | Gabriel K Griffin Christopher AG Booth Katsuhiro Togami Sun Sook Chung Daniel Ssozi | 2023/6/22 |
Enhancing dendritic cells by inhibiting BCL2 | Christopher AG Booth Andrew A Lane | 2023/9/30 | |
Organ Involvement in BPDCN Is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival | Blood | Shai Shimony Julia Keating Christopher Fay Marlise R Luskin Donna S Neuberg | 2023/11/28 |
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need | Blood | Naveen Pemmaraju Hagop Kantarjian Kendra Sweet Eunice Wang Jayastu Senapati | 2023/2/9 |
Genomics of PDGFR-rearranged hypereosinophilic syndrome | Blood advances | Esther Rheinbay Meifang Qi Juliette M Bouyssou Andrew J Oler Lauren Thumm | 2023/6/13 |
AML-303 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis … | Clinical Lymphoma Myeloma and Leukemia | Naveen Pemmaraju Marina Konopleva Kendra Sweet Anthony Stein Sumithira Vasu | 2023/9/1 |
Co-Authors
